Tesamorelin/Impamorelin 5mg/5mg

Tesamorelin + Ipamorelin 5mg/5mg — Research Blend

This research blend combines Tesamorelin (a GHRH analogue) with Ipamorelin (a selective GH secretagogue) in a dual-mechanism formulation. Tesamorelin activates GHRH receptors to stimulate GH synthesis, while Ipamorelin activates ghrelin/GHSR receptors — together producing synergistic GH release greater than either compound alone.

Tesamorelin is FDA-approved (as Egrifta) for HIV-associated lipodystrophy, giving it one of the strongest clinical research foundations of any GHRH analogue. Ipamorelin is notable for its exceptional selectivity — potent GH release without significant cortisol, ACTH, or prolactin elevation.

Combined: 5mg Tesamorelin + 5mg Ipamorelin per vial. ≥99% purity, lyophilized. For research purposes only.